References

Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions

10.1093/neuonc/noac118 · 2022 · External reference

Central nervous system metastases in HER-2–positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors

10.1634/theoncologist.12-7-766 · 2007 · External reference

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER

10.1158/1078-0432.ccr-10-2962 · 2011 · External reference

Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer

10.1038/s41571-023-00808-4 · 2023 · External reference

Defining the hallmarks of metastasis

10.1158/0008-5472.can-19-0458 · 2019 · External reference

Real-time imaging reveals the single steps of brain metastasis formation

10.1038/nm.2072 · 2010 · External reference

The vascular basement membrane as “soil” in brain metastasis

10.1371/journal.pone.0005857 · 2009 · External reference

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF

10.1126/science.284.5422.1994 · 1999 · External reference

Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option

10.1158/1078-0432.ccr-04-0823 · 2004 · External reference

The biology of brain metastases—translation to new therapies

10.1038/nrclinonc.2011.58 · 2011 · External reference

Heterogeneous blood–tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer

10.1158/1078-0432.ccr-10-1564 · 2010 · External reference

The blood–brain barrier and blood–tumour barrier in brain tumours and metastases

10.1038/s41568-019-0205-x · 2020 · External reference

Drug delivery to the central nervous system

10.1038/s41578-021-00394-w · 2022 · External reference

Unraveling the role of angiogenesis in cancer ecosystems

10.3389/fonc.2018.00248 · 2018 · External reference

The evolving landscape of brain metastasis

10.1016/j.trecan.2018.01.003 · 2018 · External reference

The immune landscape in brain metastasis

10.1093/neuonc/noae219 · 2025 · External reference

Immunologic tumor microenvironment modulators for turning cold tumors hot

10.1002/cac2.12539 · 2024 · External reference

Cold and hot tumors: from molecular mechanisms to targeted therapy

10.1038/s41392-024-01979-x · 2024 · External reference

Oligometastases revisited

10.1038/nrclinonc.2011.44 · 2011 · External reference

The oligometastatic spectrum in the era of improved detection and modern systemic therapy

10.1038/s41571-022-00655-9 · 2022 · External reference

A cure is possible: a study of 10-year survivors of brain metastases

10.1007/s11060-016-2208-8 · 2016 · External reference

Influence of brain metastases on the classification, treatment, and outcome of patients with extracranial oligometastasis: a single-center cross-sectional analysis

10.1186/s13014-024-02542-2 · 2024 · External reference

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study

10.1182/blood-2015-02-626788 · 2015 · External reference

The biology of metastasis to a sanctuary site

10.1158/1078-0432.ccr-06-2659 · 2007 · External reference

Intracranial and extracranial progression and their correlation with overall survival after stereotactic radiosurgery in a multi-institutional cohort with brain metastases

10.1001/jamanetworkopen.2023.10117 · 2023 · External reference

Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival

10.1093/neuonc/noaa025 · 2020 · External reference

Molecular evolution of central nervous system metastasis and therapeutic implications

10.1016/j.molmed.2024.09.008 · 2025 · External reference

Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring

10.1200/edbk-25-481114 · 2025 · External reference

Does graded Prognostic assessment outperform recursive partitioning analysis in patients with moderate prognosis brain metastases?

10.2217/cns.15.45 · 2016 · External reference

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

10.1200/jco.2011.38.0527 · 2012 · External reference

Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)

10.1001/jamaoncol.2016.3834 · 2017 · External reference

10.1016/j.ijrobp.2022.03.020

10.1016/j.ijrobp.2022.03.020 · 2022 · External reference

Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases

10.1016/j.ijrobp.2011.02.027 · 2012 · External reference

Beyond an updated graded prognostic assessment (breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today

10.1016/j.ijrobp.2020.01.051 · 2020 · External reference

Improved survival and prognostication in melanoma patients with brain metastases: an update of the melanoma graded prognostic assessment

10.1200/jco-24-01351 · 2025 · External reference

Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA)

10.1016/j.ijrobp.2017.06.2454 · 2017 · External reference

Effect of targeted therapies on prognostic factors, patterns of care, and survival in patients with renal cell carcinoma and brain metastases

10.1016/j.ijrobp.2018.04.006 · 2018 · External reference

Estimating survival for renal cell carcinoma patients with brain metastases: an update of the renal graded prognostic assessment tool

10.1093/neuonc/noy099 · 2018 · External reference

Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the response assessment in neuro-oncology brain metastases working group

10.1016/s1470-2045(17)30693-9 · 2018 · External reference

BMScope: a scoping review to chart the evolving clinical study landscape in brain and leptomeningeal metastasis

10.1093/neuonc/noae140 · 2024 · External reference

Central nervous system metastases in advanced non-small cell lung cancer: a review of the therapeutic landscape

10.1016/j.ctrv.2024.102807 · 2024 · External reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

10.1016/j.ejca.2008.10.026 · 2009 · External reference

Response assessment criteria for brain metastases: proposal from the RANO group

10.1016/s1470-2045(15)70057-4 · 2015 · External reference

CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: data from a randomized phase III trial (AURA3)

10.1200/jco.2018.77.9363 · 2018 · External reference

CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non–small-cell lung cancer

10.1200/jco.2018.78.3118 · 2018 · External reference

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

10.1016/s1470-2045(21)00545-3 · 2021 · External reference

Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets

10.1158/2159-8290.cd-15-0369 · 2015 · External reference

Oncogenic alterations in advanced NSCLC: a molecular super-highway

10.1186/s40364-024-00566-0 · 2024 · External reference

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

10.1016/s1470-2045(20)30111-x · 2020 · External reference

Phase II trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non–small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17/05)

10.1200/jco.22.02561 · 2023 · External reference

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China

10.1016/j.eclinm.2025.103638 · 2025 · External reference

Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapy

10.21037/tlcr-23-687 · 2024 · External reference

Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC

10.1056/nejmoa1716948 · 2018 · External reference

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

10.1016/j.jtho.2021.09.014 · 2022 · External reference

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

10.1016/j.ejca.2024.114296 · 2024 · External reference

Unresolved reference

2018 · External reference

Biomarkers of osimertinib response in patients with refractory, EGFR-T790M–positive non–small cell lung cancer and central nervous system metastases: the APOLLO study

10.1158/1078-0432.ccr-20-2081 · 2020 · External reference

A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis from NSCLC: results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L)

10.1016/j.jtho.2021.07.026 · 2021 · External reference

A phase 2 single-arm study of osimertinib for radiotherapy-naive central nervous system metastasis NSCLC: results for the first-line cohort of the OCEAN study (LOGIK 1603/WJOG 9116L)

10.1016/j.jtocrr.2023.100587 · 2023 · External reference

CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor–mutated advanced non–small-cell lung cancer

10.1200/jco.23.02219 · 2024 · External reference

Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC

10.1056/nejmoa2306434 · 2023 · External reference

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

10.1093/noajnl/vdab188 · 2022 · External reference

Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and-negative non-small cell lung cancer patients: results from a phase II study

10.1080/0284186x.2021.1973092 · 2021 · External reference

Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-mutant non–small-cell lung cancer

10.1200/jco.23.01521 · 2024 · External reference

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

10.1016/s1470-2045(12)70086-4 · 2012 · External reference

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

10.1200/jco.2012.44.2806 · 2013 · External reference

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

10.1016/s1470-2045(16)30033-x · 2016 · External reference

First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases

10.1016/j.jtho.2015.11.014 · 2016 · External reference

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations

10.3389/fonc.2023.1094195 · 2023 · External reference

Intracranial responses to afatinib at different doses in patients with EGFR-mutated non–small-cell lung carcinoma and brain metastases

10.1016/j.cllc.2019.02.009 · 2019 · External reference

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

10.1186/s12885-018-5110-2 · 2018 · External reference

Unresolved reference

2018 · External reference

Unresolved reference

External reference

Amivantamab plus lazertinib in patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A

10.1016/j.jtho.2024.12.029 · 2025 · External reference

Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases

10.1016/j.jtho.2025.10.012 · 2026 · External reference

Overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC

10.1056/nejmoa2503001 · 2025 · External reference

Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC

10.1056/nejmoa2403614 · 2024 · External reference

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

10.1016/j.annonc.2023.10.117 · 2024 · External reference

Unresolved reference

2024 · External reference

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers

10.1016/j.lungcan.2015.01.020 · 2015 · External reference

Genomic alterations and the incidence of brain metastases in advanced and metastatic NSCLC: a systematic review and meta-analysis

10.1016/j.jtho.2023.06.017 · 2023 · External reference

Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non–small-cell lung cancer: results from PROFILE 1014

10.1200/jco.2015.63.5888 · 2016 · External reference

Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases

10.1200/jco.2014.59.0539 · 2015 · External reference

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

10.1016/j.annonc.2020.04.478 · 2020 · External reference

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

10.1016/s2213-2600(19)30053-0 · 2019 · External reference

Efficacy and safety of brigatinib compared with crizotinib in Asian vs. non-Asian patients with locally advanced or metastatic alk–inhibitor-naive alk+ non–small cell lung cancer: final results from the phase III ALTA-1L study

10.1016/j.cllc.2022.07.008 · 2022 · External reference

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial

10.1001/jamaoncol.2021.3523 · 2021 · External reference

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

10.1016/s0140-6736(17)30123-x · 2017 · External reference

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

10.1016/s1470-2045(17)30339-x · 2017 · External reference

Lorlatinib versus crizotinib in patients with advanced ALK-positive non–small cell lung cancer: 5-year outcomes from the phase III CROWN study

10.1200/jco.24.00581 · 2024 · External reference

Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in people's Republic of China

10.1016/j.jtho.2022.02.014 · 2022 · External reference

Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study

10.1016/j.esmoop.2021.100342 · 2022 · External reference

Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

10.1038/s41467-025-59744-9 · 2025 · External reference

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial

10.1016/j.lungcan.2025.108683 · 2025 · External reference

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

10.1016/s0140-6736(25)00866-9 · 2025 · External reference

Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRASG12C-mutated non–small-cell lung cancer who have untreated CNS metastases

10.1200/jco.23.00046 · 2023 · External reference

Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRASG12C-mutant non–small cell lung cancer

10.1158/1078-0432.ccr-22-0383 · 2022 · External reference

Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non–small-cell lung cancer: 2-year analysis of CodeBreaK 100

10.1200/jco.22.02524 · 2023 · External reference

Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced NSCLC: results from a phase 2 pivotal study

10.1016/j.jtho.2024.08.005 · 2024 · External reference

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: the IFCT-2102 lung KG12Ci study

10.1016/j.ejca.2025.115301 · 2025 · External reference

Unresolved reference

2024 · External reference

BI-3406, a potent and selective SOS1–KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition

10.1158/2159-8290.cd-20-0142 · 2021 · External reference

Selpercatinib in RET fusion–positive non–small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I/II trial

10.1200/jco-24-02076 · 2025 · External reference

Intracranial efficacy of selpercatinib in RET fusion-positive non–small cell lung cancers on the LIBRETTO-001 trial

10.1158/1078-0432.ccr-21-0800 · 2021 · External reference

Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer

10.1056/nejmoa2005653 · 2020 · External reference

First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC

10.1056/nejmoa2309457 · 2023 · External reference

Intracranial activity of selpercatinib in Chinese patients with advanced RET fusion–positive Non–small-cell lung cancer in the phase II LIBRETTO-321 trial

2023 · External reference

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

10.1016/s1470-2045(21)00247-3 · 2021 · External reference

Taletrectinib in ROS1+ non–small cell lung cancer: TRUST

10.1200/jco-25-00275 · 2025 · External reference

Repotrectinib in ROS1 fusion–positive non–small-cell lung cancer

10.1056/nejmoa2302299 · 2024 · External reference

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

10.1016/j.esmoop.2024.102237 · 2024 · External reference

Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study

10.1016/j.esmoop.2024.103642 · 2024 · External reference

Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion–positive non–small-cell lung cancer

10.1200/jco.20.03025 · 2021 · External reference

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial

10.1016/s1470-2045(19)30655-2 · 2019 · External reference

A phase 2 study of lorlatinib in patients with ROS1-rearranged lung cancer with brain-only progression on crizotinib

2022 · External reference

Open-label, multicenter, phase II study of ceritinib in patients with non–small-cell lung cancer harboring ROS1 rearrangement

10.1200/jco.2016.71.3701 · 2017 · External reference

Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer

10.1016/j.lungcan.2023.107442 · 2024 · External reference

Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial

10.1016/j.eclinm.2023.101952 · 2023 · External reference

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial

10.1016/s1470-2045(24)00441-8 · 2024 · External reference

Tepotinib treatment in patients with MET exon 14–skipping non–small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial

10.1001/jamaoncol.2023.1962 · 2023 · External reference

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (MET ex14) skipping NSCLC enrolled in VISION

10.1093/noajnl/vdab071.021 · 2021 · External reference

Intracranial activity of tepotinib in patients (pts) with MET exon 14 (MET ex14) skipping NSCLC enrolled in VISION

10.1200/jco.2021.39.15_suppl.9084 · 2021 · External reference

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

10.1016/s1470-2045(12)70432-1 · 2013 · External reference

The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systematic review and pooled analysis

10.1016/j.ejca.2017.07.024 · 2017 · External reference

TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases

10.1200/jco.18.01511 · 2019 · External reference

Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial

10.1001/jamaoncol.2016.0237 · 2016 · External reference

Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial

10.1200/jco.20.00147 · 2020 · External reference

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

10.1056/nejmoa1914609 · 2020 · External reference

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

10.1200/jco.20.00775 · 2020 · External reference

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial

10.1001/jamaoncol.2022.5610 · 2023 · External reference

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial

10.1016/j.eclinm.2024.102837 · 2024 · External reference

Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study

10.21037/tbcr-20-25 · 2020 · External reference

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial

10.1016/j.annonc.2020.06.020 · 2020 · External reference

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis

10.1158/2159-8290.cd-22-0837 · 2022 · External reference

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

10.1016/j.esmoop.2024.102924 · 2024 · External reference

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

10.1038/s41591-024-03261-7 · 2024 · External reference

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

10.1038/s41591-022-01935-8 · 2022 · External reference

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

2024 · External reference

Efficacy of disitamab vedotin (RC48) for previously treated human epidermal growth factor receptor 2-positive breast cancer with symptomatic brain metastases: a case report and review of the literature

10.1097/cad.0000000000001702 · 2025 · External reference

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China

10.1016/j.eclinm.2025.103614 · 2025 · External reference

Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP)

10.1200/jco.24.00529 · 2025 · External reference

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

10.1016/s1470-2045(22)00621-0 · 2022 · External reference

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study

10.1016/s1470-2045(24)00735-6 · 2025 · External reference

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

10.1016/s1470-2045(18)30139-6 · 2018 · External reference

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

10.1016/s1470-2045(17)30429-1 · 2017 · External reference

Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

10.1016/j.ejca.2024.113531 · 2024 · External reference

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

10.1016/s1470-2045(23)00334-0 · 2023 · External reference

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: checkmate 920

10.1002/cncr.34016 · 2022 · External reference

Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study

10.1200/jco.18.02218 · 2019 · External reference

Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab

10.1136/jitc-2021-003281 · 2021 · External reference

Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET

10.1016/j.ejca.2026.116712 · 2026 · External reference

Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma

10.1001/jamaoncol.2021.4544 · 2021 · External reference

Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population

10.1016/j.clgc.2019.05.002 · 2019 · External reference

Unresolved reference

2020 · External reference

Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases

10.1093/noajnl/vdad018 · 2023 · External reference

Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study

10.1136/jitc-2024-011432 · 2025 · External reference

Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases

10.1016/j.ijrobp.2017.05.028 · 2017 · External reference

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

10.1136/jitc-2023-006871 · 2023 · External reference

Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases

10.1016/j.ijrobp.2023.01.017 · 2023 · External reference

Adverse radiation effect and disease control in patients undergoing stereotactic radiosurgery and immune checkpoint inhibitor therapy for brain metastases

10.1016/j.wneu.2019.03.110 · 2019 · External reference

Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma

10.1016/j.ijrobp.2017.11.041 · 2018 · External reference

The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis

10.1093/neuonc/noz046 · 2019 · External reference

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation therapy oncology group 0320

10.1016/j.ijrobp.2012.11.042 · 2013 · External reference

Combination of EGFR-directed tyrosine kinase inhibitors (EGFR-TKI) with radiotherapy in brain metastases from non-small cell lung cancer: a 2010–2019 retrospective cohort study

10.3390/cancers15113015 · 2023 · External reference

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials

10.1016/j.jtho.2026.01.001 · 2026 · External reference

Radiation therapy combined with tyrosine kinase inhibitors in 826 patients with HER2-positive breast cancer brain metastases: a systematic review and network meta-analysis

10.1007/s10143-025-04097-6 · 2026 · External reference

Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial

10.1186/s12885-025-15224-3 · 2025 · External reference

Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2+ breast cancer

10.1007/s11060-022-04055-y · 2022 · External reference

Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases

10.1038/s41523-024-00711-w · 2024 · External reference

Trastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of COMBART prospective cohort study

10.1093/oncolo/oyaf229 · 2025 · External reference

Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohort

10.1016/j.breast.2026.104691 · 2026 · External reference

Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report

10.1007/s11060-025-05230-7 · 2025 · External reference

Unresolved reference

2025 · External reference

Consistent opening of the blood brain barrier using focused ultrasound with constant intravenous infusion of microbubble agent

10.1038/s41598-020-73312-9 · 2020 · External reference

Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model

10.1016/j.jconrel.2012.09.007 · 2012 · External reference

Focused ultrasound delivers targeted immune cells to metastatic brain tumors

10.1158/0008-5472.can-12-2609 · 2013 · External reference

Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier

10.1038/s41467-024-52329-y · 2024 · External reference

Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption

10.1016/j.jconrel.2016.08.001 · 2016 · External reference

Blood-tumor barrier opening by MRI-guided transcranial focused ultrasound in a preclinical breast cancer brain metastasis model improves efficacy of combinatorial chemotherapy

10.3389/fonc.2023.1104594 · 2023 · External reference

Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival

10.1093/neuonc/nov318 · 2016 · External reference

MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases

10.1126/scitranslmed.abj4011 · 2021 · External reference

Lipsman N. P07.13.B A randomized study of low-intensity focused ultrasound for blood-brain disruption for brain metastasis from non-small cell lung cancer (limitless)

10.1093/neuonc/noad137.173 · 2023 · External reference

Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial

10.1038/s41467-024-45818-7 · 2024 · External reference

Focused ultrasound therapy as a strategy for improving glioma treatment

10.3171/2024.9.jns24721 · 2025 · External reference

Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study

10.1038/s41598-018-36340-0 · 2019 · External reference

Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study

10.1016/j.ijrobp.2025.08.066 · 2026 · External reference

Tumor treating fields (TTFields) after stereotactic radiosurgery (SRS) for brain metastases from non-small cell lung cancer (NSCLC BM): final results of the phase 3 METIS trial

10.1016/j.ijrobp.2025.08.027 · 2025 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Bispecific antibody drug conjugates: Making 1+1>2

10.1016/j.apsb.2024.01.009 · 2024 · External reference

Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle

10.1016/j.neuron.2013.10.061 · 2014 · External reference